BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Biosergen has been approved for listing on Nasdaq First North Growth Market. The first day of trading will be June 24, 2021. Biosergens shares will be traded under the short name “BIOSGN” with the ISIN code SE0016013460. The warrants of series TO1 will be traded under the short name “BIOSGN TO1” with the ISIN code SE0016013478. The Company’s shareholders and holders of warrants are not required to do anything in this connection.  

Bell ringing ceremony

Biosergen invites those interested to participate online at the Nasdaq bell ringing ceremony from 8.30 on June 24, 2021. Please use the details below to enter the Zoom meeting:

Link:                      Join Zoom Meeting

Meeting ID:           935 8601 1637

Password:              Nasdaq

Certified Adviser

Erik Penser Bank

Telephone: +46 8 463 8000

E-mail: certifiedadviser@penser.se

For further information, please contact:

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470
E-mail: pma@biosergen.net

ABOUT BIOSERGEN

Biosergen is a No-Research-Development-Only biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has applied for orphan drug status for BSG005 and expects to file the NDA by the end of 2025.